NCT05661942CompletedPhase 4
Diltiazem in the Treatment of Atrial Fibrillation or Atrial Flutter With Rapid Ventricular Rate
Diltiazem in the Treatment of Atrial Fibrillation or Atrial Flutter With Rapid Ventricular Rate (AFF RVR): Comparing Calcium Pre-treatment vs Placebo in Prevention of Diltiazem Induced Hypotension
Source: ClinicalTrials.gov · Last updated 10 Nov 2025
Brief summary (registry, in English)
The purpose of this study is to see how well calcium pre-treatment works for decreasing incidence of drug-induced hypotension after diltiazem administration for treatment of atrial flutter with rapid ventricular rate.
- Status (registry)
- Completed
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 92 (actual)
- First submitted
- 15 Dec 2022
- Start date
- 30 Nov 2022
- Primary completion date
- 20 Nov 2024
- Lead sponsor
- Wake Forest University Health Sciences
- Diseases
- Atrial fibrillation
- NCT number
- NCT05661942
What you commit to
- Study type: Interventional · Phase 4
- Participants enrolled: 92
- From 30 Nov 2022 to the primary completion date, 20 Nov 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previously enrolled in this trial during a different patient encounter
Other illness
- Sinus node dysfunction or preexcitation with accessory pathway (known diagnosis of SVT, WPW or sick sinus syndrome. Delta waves or other evidence of accessory pathway on EKG)
- Allergy or sensitivity to any study drugs
Lab values
- Stated history of systolic heart failure with reduced ejection fraction (\<40%) or evidence of acute heart failure or reduced EF (peripheral edema, JVD, pulmonary edema) on clinical exam or bedside echo
Other
- Pregnancy defined as a positive urine HCG
- Hemodynamically unstable patients (SBP \<90, MAP \<65)
- Patients with left ventricular assist device
- 2nd or 3rd degree atrioventricular block
- Non-English speaking
Who the study is looking for
- Age \> 18 years or older
- Able to provide informed consent
- Primary diagnosis AFF with RVR greater than or equal to 120 bpm
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Advocate Christ Medical Center Emergency Department (ACMC ED) Coordinator of this site? Confirm its status | Oak Lawn | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.